Harsh V. Parmar

Oncology | Hematology
92 2nd Street
Hackensack, NJ 7601.

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Characterization and prognostic implications of infections associated with T-cell engagers in multiple myeloma.

Characterization and prognostic implications of infections associated with T-cell engagers in multiple myeloma.

Journal: Leukemia & lymphoma
Published: August 11, 2026

Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.

Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.

Journal: Current oncology (Toronto, Ont.)
Published: June 27, 2026

Using cell-free RNA to identify B- and T-cell clonality for diagnosis and monitoring of B- and T-cell neoplasms.

Using cell-free RNA to identify B- and T-cell clonality for diagnosis and monitoring of B- and T-cell neoplasms.

Journal: FEBS open bio
Published: June 07, 2026

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Journal: Cancers
Published: May 18, 2026

Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma.

Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma.

Journal: Transplantation and cellular therapy
Published: March 11, 2026

Trends in Mortality Rates From Hemophagocytic Lymphohistiocytosis in the United States From 2010 to 2023.

Trends in Mortality Rates From Hemophagocytic Lymphohistiocytosis in the United States From 2010 to 2023.

Journal: Cureus
Published: February 10, 2026

Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.

Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.

Journal: European journal of haematology
Published: January 09, 2026

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Journal: Leukemia & lymphoma
Published: December 02, 2025

Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.

Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.

Journal: Blood advances
Published: November 03, 2025

Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.

Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.

Journal: Blood advances
Published: November 03, 2025

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.

Journal: Leukemia & lymphoma
Published: January 05, 2025

A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma.

A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma.

Journal: Haematologica
Published: November 27, 2024
Showing 1-12 of 31

Last Updated: 09/26/2026